DC
CTNM

Diametric Capital’s Contineum Therapeutics CTNM Stock Holding History

Diametric Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Buy
+10,729
New +$144K 0.04% 403

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Diametric Capital's CTNM Position: Q1 2026 in Review

Diametric Capital opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 10,729 shares worth $140K. The stake represents 0.04% of the portfolio and ranks #403 among its holdings.

90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Diametric Capital held 10,729 shares of Contineum Therapeutics worth $140K as of Q1 2026.
  • Contineum Therapeutics was a new Diametric Capital position in Q1 2026.
  • Contineum Therapeutics made up 0.04% of Diametric Capital's portfolio in Q1 2026, its #403 holding.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.